Abstract
A novel schedule of 5-fluorouracil administration has been developed for biochemical modulation studies. In combination with the pyrimidine synthesis inhibitor PALA, 5-fluorouracil has been given as a 24-hour infusion, repeated weekly: a dose of 2600 mg/m2 is well tolerated. To identify a suitable dose of 5-fluorouracil as a single agent on this schedule, we treated 26 patients at doses ranging from 2800 to 3400 mg/m2 per week. Two-thirds of the patients had failed previous therapy, and most were symptomatic from their disease. Over half of the patients had metastatic colorectal cancer. The dose-limiting toxicity was diarrhea: Grade 3 or 4 toxicity occurred at every level tested. Twenty-two of the 26 patients required therapy interruption because of toxicity. The severity of this toxicity indicated that escalation of 5-fluorouracil on this schedule beyond the 2600 mg/m2 known to be tolerated in the PALA-containing regimen, would be impractical. Two patients, both with previously untreated colorectal cancer, had partial remissions lasting three and five months respectively. This dose-intense schedule of 5-fluorouracil administration will be explored further in large-scale randomized trials.
Similar content being viewed by others
References
Seifert P, Baker L, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123–128, 1975
Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G. A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34–40, 1977
Lokich JJ, Bothe H, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565–2568, 1981
Caballero GA, Ausman RK, Quebbeman EJ. Long-term ambulatory continuous intravenous infusion of 5-fluorouracil for the treatment of advanced adenocarcinoma. Cancer Treat Rep 69:13–15, 1985
O'Dwyer PJ, Comis RC. Schedule as a determinant of cytotoxic anticancer drug activity. Current Opinion in Oncology 1:174–178, 1989
Cohen AM, Shank B, Friedman MA. Colorectal Cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. Lippincott, Philadelphia, 1989, pp. 895–964.
Hansen R, Ryan L, Anderson T, Quebbeman E, Haller D. A Phase III trial of bolus 5-FU versus protracted infusion 5-FU +/− cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST-2286). Proc Am Soc Clin Oncol 11:171, 1992
Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. Arandomized trial of cisplatin + 5-fluorouracil infusion and cisplatin + 5-fluorouracil bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740–2744, 1985
Ardalan B, Singh G, Silberman H. Arandomized Phase I and II study of short-term infusion of high-dose fluorouracil with or with N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053–1058, 1988
O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of Biochemical Modulation of 5-Fluorouracil by low-dose PALA in patients with colorectal cancer. Journal of Clinical Oncology 8:1497–1503, 1990
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47:207–214, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haas, N.B., Hines, J.B., Hudes, G.R. et al. Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11, 181–185 (1993). https://doi.org/10.1007/BF00874152
Issue Date:
DOI: https://doi.org/10.1007/BF00874152